Τετάρτη, 20 Μαρτίου 2019

Clinical Trials

Ono enters into research collaboration agreement with twoXAR
Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and The post Ono enters into research collaboration agreement with twoXAR appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 19, 2019 14:49
Genentech gets FDA nod for Tecentriq plus chemotherapy to treat ES-SCLC
Tecentriq monoclonal antibody has been approved in combination with carboplatin and etoposide as a first-line treatment for adults with ES-SCLC. The approval was based on data from the The post Genentech gets FDA nod for Tecentriq plus chemotherapy to treat ES-SCLC appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 19, 2019 10:44
Imara closes $63m Series B cross-over financing
The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates, The post Imara closes $63m Series B cross-over financing appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 19, 2019 10:44
Study finds widely used heart drug increases risk of sudden cardiac arrest
The findings of the study, called European Sudden Cardiac Arrest network (ESCAPE-NET), were presented at European Heart Rhythm Association (EHRA) 2019. It evaluated if nifedipine and amlodipine – The post Study finds widely used heart drug increases risk of sudden cardiac arrest appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 19, 2019 10:44
European Commission approves Roche's MabThera for rare autoimmune disease
Extensive blistering can lead to serious, life-threatening fluid loss, infection and/or death. MabThera is the first biologic therapy approved by the European Commission for PV and the first The post European Commission approves Roche's MabThera for rare autoimmune disease appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 18, 2019 14:15
Blackstone to buy Japanese specialty pharmaceutical firm Ayumi
Based in Tokyo, Ayumi is engaged in the manufacturing and marketing of various drug products for anti-rheumatism and orthopedic pain management. Citing a person familiar with the matter, The post Blackstone to buy Japanese specialty pharmaceutical firm Ayumi appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 18, 2019 12:13
Biohaven enrolls first patient in phase 3 Spinocerebellar Ataxia clinical trial of Troriluzole
Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and The post Biohaven enrolls first patient in phase 3 Spinocerebellar Ataxia clinical trial of Troriluzole appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Mon Mar 18, 2019 10:11
Merck KGaA to use Iktos AI technology across three drug discovery projects
Under The collaboration agreement will enable Merck to use Iktos generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of new compounds. The agreement The post Merck KGaA to use Iktos AI technology across three drug discovery projects appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Mar 15, 2019 12:32
Xeris Pharmaceuticals doses first patient in phase 2 trial to assess ready-to-use glucagon
"Many individuals with diabetes treated with insulin experience EIH and the complexity of managing it is a major barrier to the adoption of regular physical activity. And unfortunately, The post Xeris Pharmaceuticals doses first patient in phase 2 trial to assess ready-to-use glucagon appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Mar 15, 2019 10:30
European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Hemlibra can be used in all age groups, and can also now be used at multiple dosing options (once weekly, every two weeks, or every four weeks) for The post European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Mar 15, 2019 10:30
Esperion unveils positive human trial results for new cholesterol-lowering drug
Esperion said that bempedoic acid is under development as a complementary, cost-effective, once-daily and oral therapy to treat patients with elevated LDL-C. The company has submitted new drug The post Esperion unveils positive human trial results for new cholesterol-lowering drug appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 14, 2019 09:58
BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson's disease
The Phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805. ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed The post BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson's disease appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 14, 2019 09:58
Parkinson's disease study reveals how cancer drug reduces toxic protein in brain
The research team used a single low dose of Novartis' leukemia drug Tasigna (nilotinib) in a phase II clinical trial in Parkinson's disease patients. The researchers claimed that The post Parkinson's disease study reveals how cancer drug reduces toxic protein in brain appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Mar 14, 2019 09:58
FDA approves Dupixent for moderate-to-severe atopic dermatitis in adolescents
Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control The post FDA approves Dupixent for moderate-to-severe atopic dermatitis in adolescents appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 13, 2019 11:28
Fujifilm to buy Biogen's Danish biologics manufacturing site for $890m
Upon completion of the transaction, Biogen Hillerød will become the fourth biopharmaceutical contract development and manufacturing site of Fujifilm. The large-scale biologics manufacturing facility is installed with 6 The post Fujifilm to buy Biogen's Danish biologics manufacturing site for $890m appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 13, 2019 11:28
Sanofi's Dupixent secures FDA priority review for CRSwNP
The priority review for Dupixent is for the treatment of adult patients whose CRSwNP is inadequately controlled. CRSwNP is a chronic disease of the upper airway. It is The post Sanofi's Dupixent secures FDA priority review for CRSwNP appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 13, 2019 11:28
Lilly's CYRAMZA meets primary endpoint in phase 3 RELAY trial
The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with The post Lilly's CYRAMZA meets primary endpoint in phase 3 RELAY trial appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Wed Mar 13, 2019 09:25
Seres, AstraZeneca to collaborate on microbiome immuno-oncology
According to Seres Therapeutics, the partners will research to assess microbiome-based approaches as a predictor for which cancer immunotherapies get the best response from patients. In addition, the The post Seres, AstraZeneca to collaborate on microbiome immuno-oncology appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 12, 2019 15:00
Tenax Therapeutics recruits first patient in phase 2 pulmonary hypertension clinical trial
The study, also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF), is designed to enroll a total of 36 PH-HFpEF patients at up The post Tenax Therapeutics recruits first patient in phase 2 pulmonary hypertension clinical trial appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Tue Mar 12, 2019 12:58

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις